Cervomed announces orphan drug designation granted to neflamapimod by u.s. food and drug administration for the treatment of frontotemporal dementia

Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders

CRVO Ratings Summary

CRVO Quant Ranking